GlobeNewsWire
06 Oct 2025, 22:01 UTC · 50w ago
Verdict
Headline takes no side. We score DYN +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
A registrational expansion cohort has been initiated for zeleciment basivarsen to support potential regulatory submissions, including Accelerated Approval in the U.S.
More positive than 99% of claims this week
One-year data from the 6.8 mg/kg Q8W registrational dose cohort demonstrated clinically meaningful improvements in function and strength across upper and lower limbs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 98% of claims this week
Zeleciment basivarsen has been granted Breakthrough Therapy, Orphan Drug, and Fast Track designations by the U.S. FDA, as well as Orphan Drug designation by the EMA.
More positive than 93% of claims this week
Patient-reported outcomes indicate that the improvements in function and strength are clearly meaningful to patients and physicians, increasing confidence in the drug's broad effect.
More positive than 86% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced robust clinical improvements in function and strength for its DM1 drug candidate in the ACHIEVE trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market Watch
23h ago
+28.3%
Price agrees with the score
$16.23 vs $12.65 close before publication (Oct 6) · not market-adjusted
DYN chart →
